Clinical trial
Phase II Study of Antineoplastons A10 and AS2-1 Capsules With Total Androgen Blockade in Patients With Stage III or IV Adenocarcinoma of the Prostate
NCT00003517 is registered in ClinicalTrials.gov with Burzynski Research Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Study of Antineoplastons A10 and AS2-1 Capsules With Total Androgen Blockade in Patients With Stage III or IV Adenocarcinoma of the Prostate
- Lead sponsor
- Burzynski Research Institute
- Phase
- Phase 2
- Overall status
- Withdrawn
- Start date
- Not reported
- Completion date
- Not reported
- Enrollment
- 0 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
adenocarcinoma of the prostate, recurrent prostate cancer, stage iii prostate cancer, stage iv prostate cancer